Vanda's NEREUS Launch Coincides With Unrelated Spike in Atossa Shares
Shares of Atossa Genetics rose 10.3% Monday in a move that appears disconnected from company fundamentals and may reflect investor confusion with Vanda Pharmaceuticals, which said it has commercially launched NEREUS (tradipitant) across the United States for prevention of vomiting due to motion in adults. Vanda described the drug as the first new p…